Melanoma preferentially expressed antigen (PRAME) is highly expressed in patients with liver cancer, and studies have found that Evo can inhibit tumor metastasis by inhibiting the expression of PRAME (Zhu et al., 2019). The gene discussed is PRAME; the disease is liver cancer.